Prostate Cancer Clinical Trial
Enzalutamide vs. Abiraterone in Chemotherapy-naÃ¯ve Metastatic Castration-resistant Prostate Cancer (mCRPC)
This study will be a retrospective data analysis to compare outcomes between patients with chemotherapy-naÃ¯ve metastatic castration-resistant prostate cancer (mCRPC) who initiated enzalutamide and those who initiated abiraterone using the 100% Fee-For-Service Medicare claims data. The study will address the following objectives:
Primary objective: To compare overall survival (OS) in patients with chemotherapy-naÃ¯ve mCRPC who initiated enzalutamide vs. abiraterone
To compare OS in patients with chemotherapy-naÃ¯ve mCRPC who received only enzalutamide without any subsequent therapy vs. abiraterone without any subsequent therapy
To compare treatment duration and time to subsequent therapy in chemotherapy-naÃ¯ve mCRPC patients initiating enzalutamide vs. abiraterone
Male with â‰¥ 1 diagnosis claim for prostate cancer
Have documented secondary metastasis code on or after the initial prostate cancer diagnosis
Have initiated enzalutamide or abiraterone within 90 days prior to the metastasis date or on or after the metastasis date. The initiation date of enzalutamide or abiraterone will be defined as the index date.
Have evidence of surgical or medical castration before the index date
At least 18 years old at the index date
Continuous eligibility for â‰¥ 12 months prior to the index date
Received chemotherapy, novel hormonal therapy, radium-223, or immunotherapy prior to the index date
Had a prior history of other cancers
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10017, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.